SCHEMBL21682009

SCHEMBL21682009

O=C(Nc1nc2ccc(Cl)cc2s1)c1ccc2ccccc2c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 7/20 0.65
SENP8 Q96LD8 7/20 0.65
SENP7 Q9BQF6 7/20 0.65
SENP6 Q9GZR1 7/20 0.65
MMP13 P45452 1/20 0.65
LRRK2 Q5S007 2/20 0.63
DYRK1A Q13627 1/20 0.61
FSCN1 Q16658 1/20 0.61
RAB9A P51151 2/20 0.61
NPC1 O15118 2/20 0.61
KDM4E B2RXH2 1/20 0.61
NFKB1 P19838 1/20 0.61
NFKB2 Q00653 1/20 0.61
RELA Q04206 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
HSD17B1 P14061 1/20 0.59
HSD17B2 P37059 1/20 0.59
PRSS12 P56730 1/20 0.59
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31398557 0.86 HSD17B10 (0.67) LRRK2RAB9ANPC1SMN1; SMN2HSD17B1
SCHEMBL21772286 0.86 LCK (0.64) HSD17B1HSD17B2
SCHEMBL14807588 0.86 TOP1 (0.74) CASP3SENP8SENP7SENP6MMP13
SCHEMBL21681916 0.85 MAP3K5 (0.69) LRRK2DYRK1ARAB9ANPC1KDM4E
SCHEMBL21772299 0.83 SCD (0.76) RAB9ANPC1KDM4ESMN1; SMN2MEN1
SCHEMBL17251803 0.83 CASP3 (0.65) CASP3SENP8SENP7SENP6LRRK2
SCHEMBL4912210 0.83 SCD (0.80) RAB9ANPC1KDM4ESMN1; SMN2MEN1
SCHEMBL31398564 0.83 SCD (0.76) RAB9ANPC1KDM4ESMN1; SMN2MEN1
SCHEMBL29532955 0.83 CASP3 (0.65) CASP3SENP8SENP7SENP6LRRK2
SCHEMBL4918066 0.82 MMP13 (0.71) CASP3SENP8SENP7SENP6MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200071316-A1 ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I\" PATHWAY AND METHODS OF USE THEREOF Kineta Immuno-Oncology LLC 2020-03-05 US claimed
WO-2020033782-A1 ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-1\" PATHWAY AND METHODS OF USE THEREOF Kineta, Inc. (US) 2020-02-13 WO claimed
US-20200071316-A1 ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I\" PATHWAY AND METHODS OF USE THEREOF Kineta Immuno-Oncology LLC 2020-03-05 US disclosed
WO-2020033782-A1 ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-1\" PATHWAY AND METHODS OF USE THEREOF Kineta, Inc. (US) 2020-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200071316-A1 ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I\" PATHWAY AND METHODS OF USE THEREOF RARB, RARG, RARA CASP3 907/4885SENP8 2570/4885SENP7 2537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.